Forty Consecutive Quarters of Dose Sales Growth Globally

Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced dose sales of SIR-Spheres® microspheres grew 33 percent on a unit basis in the Americas region for the quarter ending June 30, 2014, compared to the previous corresponding period.

“Our dedication to building a team focused on a comprehensive, multidisciplinary approach to ensure optimal patient care has resulted in an outstanding performance by the Americas region,” said Mike Mangano, president of Sirtex Medical, Inc. “Adoption rates for this very important treatment option for patients continue to grow as we anticipate the results of our landmark clinical study SIRFLOX in 2015.”

Globally, Sirtex reported that dose sales of SIR-Spheres microspheres grew 27.1 percent during the same period. Gilman Wong, Sirtex CEO, said, “The successful implementation of our business strategy with appropriate investment by the company in sales and marketing, manufacturing, clinical studies and research should ensure Sirtex achieves its full potential.”

In the coming year, the Americas region will continue to focus on patient and physician education and expansion strategies into other regions supported by an emphasis on the company’s clinical studies as well as training and marketing efforts.

For more information, visit www.Sirtex.com or find the latest updates on the SIR-Spheres microspheres Facebook page (www.Facebook.com/SIRSpheresmicrospheres).

About Selective Internal Radiation Therapy using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

In the U.S., SIR-Spheres microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). SIR-Spheres microspheres are approved for use in Argentina, Brazil, Australia, the European Union and several countries in Asia for the treatment of unresectable liver tumors.

Available at more than 700 treatment centers, over 40,000 doses of SIR-Spheres microspheres have been supplied worldwide.

For more information, visit www.sirtex.com.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

For SirtexElizabeth Romero, 919-457-0749elizabeth.romero@fleishman.com

Sierra Rutile (ASX:SRX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Sierra Rutile Charts.
Sierra Rutile (ASX:SRX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Sierra Rutile Charts.